New Drug Approvals and Their Contract Manufacture - 2021 Edition

New Drug Approvals and Their Contract Manufacture - 2021 Edition

  • April 2021 •
  • 59 pages •
  • Report ID: 6067621 •
  • Format: PDF
New Drug Approvals and Their Contract Manufacture - 2021 Edition

This report is the 11th edition of our long running analysis of the CMO Industry, using NDA approvals as the primary indicator of performance.New Drug Approvals and Their Contract Manufacture (formerly called CMO Scorecard) is critical for benchmarking the performance of the CMO industry and the relative performance of major CMOs.

This year’s edition also includes a discussion of Emergency Use Aprrovals for COVID-19.

This 59-page report gives important, expert insight you won’t find in any other source. 10 tables and 30 figures throughout the report illustrate major points and trends.

This report is required reading for -
- CMO executives who must have deep understanding of the injectables marketplace to make strategic planning and investment decisions.
- Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
- Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy
- Overview of NDA drug approvals and the levels of outsourcing associated with NDA sub segments
- Detailed view of CDMO performance by number of approvals and an assessment of their sponsors market caps from Contract Service Providers database
- Outsourcing propensity for NMEs, different dosage forms and by sponsor company cap have all been assessed.
- Analysis of NME special products approvals such as those with Orphan, Breakthrough or Fast Track designations and assessment of outsourcing

We are very sorry, but an error occurred.
Please contact if the problem remains.